The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview of the New Oral Anticoagulants: Opportunities and Challenges
Abstract
The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. All 4 agents are licensed in the United States for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism and rivaroxaban and apixaban are approved for thromboprophylaxis after elective hip or knee arthroplasty. The NOACs are at least as effective as warfarin, but are not only more convenient to administer because they can be given in fixed doses without routine coagulation monitoring but also are safer because they are associated with less intracranial bleeding. As part of a theme series on the NOACs, this article (1) compares the pharmacological profiles of the NOACs with that of warfarin, (2) identifies the doses of the NOACs for each approved indication, (3) provides an overview of the completed phase III trials with the NOACs, (4) briefly discusses the ongoing studies with the NOACs for new indications, (5) reviews the emerging real-world data with the NOACs, and (6) highlights the potential opportunities for the NOACs and identifies the remaining challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366 · cited 1×
“5-mg BID dose regimens were associated with rates of major bleeding similar to that with placebo.(11) Compared with warfarin, the rate of recurrent VTE with dabigatran was similar, but the rate of major bleeding was 50% lower with dabigatran than with warfarin (0.”
BackgroundSelf-citationExtended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775 · cited 1×
“The efficacy and safety of dabigatran in this setting are comparable with those of enoxaparin, whereas apixaban is more effective than once daily enoxaparin and equally effective as twice daily enoxaparin with a similar risk of major bleeding.(5,6) Therefore, the NOACs offer a convenient alternative to enoxaparin in e…”
BackgroundGraham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
Cited by
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
A rapid pro-hemostatic approach to overcome direct oral anticoagulants
Thalji, N. K., Ivanciu, L., Davidson, R., Gimotty, P. A., Krishnaswamy, S., & Camire, R. M. (2016) · Nature Medicine · doi:10.1038/nm.4149 · Cited by 43
Sanada, F., Muratsu, J., Otsu, R., Shimizu, H., Koibuchi, N., Uchida, K., Taniyama, Y., Yoshimura, S., Rakugi, H., & Morishita, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17508-6 · Cited by 41
Metadata
- Authors
- Yeh, C. H., Hogg, K., & Weitz, J. I.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2015-05
- Volume
- 35
- Issue
- 5
- Pages
- 1056-1065
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2557845780
- Cited by
- 189
- References
- 8
- FWCI
- 16.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.